The hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-; molecular subtype luminal A) subtype is the least aggressive and most frequently diagnosed, accounting for ~68% of breast cancer cases and is very responsive to therapy. Here, ERBB2 is linked to breast cancer.